Last edition
News about "Yujiro S. Hata"
IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC
Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.
Yujiro S. Hata | 02/03/2026 | By News Bureau
Servier and IDEAYA Biosciences have entered into an exclusive license agreement to globally develop and commercialise darovasertib, a potential first-in-class therapy for uveal melanoma, with Servier taking rights outside the US and IDEAYA retaining US rights.
Yujiro S. Hata | 02/09/2025 | By Mrinmoy Dey | 205
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy